Price Target Raised on Biopharma Ahead of Leukemia Trial Update
Source: Streetwise Reports  (5/8/19)
The expected data and their implications were addressed in a ROTH Capital Partners report. More >

'Pivotal Topline Up Next' for Biotech's Phase 3 Cardiac Clinical Trial
Source: Streetwise Reports  (5/1/19)
A study update and the next steps to advance the therapeutic were covered in a ROTH Capital Partners report. More >

Immuno-Oncology Firm to Collaborate on Third Clinical Trial with Genentech
Source: Streetwise Reports  (5/1/19)
Descriptions of the new study and upcoming data readouts for this California-based firm were provided in an H.C. Wainwright & Co. report. More >

Firm's AR E-Commerce Solutions to Be Marketed, Sold to Dispensaries
Source: Streetwise Reports  (4/29/19)
With the signing of a reseller agreement, the tech firm continues to penetrate Canada's burgeoning legal cannabis industry. More >

'Undervalued' Biopharma Features Robust Pipeline, Future Upside
Source: Streetwise Reports  (4/24/19)
The case for investing in this company was made in an H.C. Wainwright & Co. report. More >

California Gold Mining Full Speed Ahead in Hemp
Source: Peter Epstein for Streetwise Reports  (4/18/19)
Peter Epstein of Epstein Research provides an update on a mining exploration company that is diversifying into the hemp market. More >

Analyst: Biopharma, Now Stronger Than Ever, Is an Ideal Takeout Target
Source: Streetwise Reports  (4/17/19)
An argument is made in a ROTH Capital Partners report for a potential imminent deal involving this drug maker. More >

Developer of Cannabinoid-Based Drugs to Resume Cancer Pain Trial
Source: Streetwise Reports  (4/17/19)
Calling this latest development "excellent news," Paradigm Capital has raised its target price on the company's stock. More >

Immunotherapeutic Agent Shows Efficacy in Rare Respiratory Disease
Source: Streetwise Reports  (4/10/19)
Trial results for this therapeutic, and their implications for this biotech, were discussed in an H.C. Wainwright & Co. report. More >

Innovative Healthcare Tech Firm to Acquire Two Vancouver Pharmacies
Source: Streetwise Reports  (4/3/19)
The transaction will allow the company to add a prescription fill and fulfillment component to its telemedicine app. More >

Biopharma Expects Data Readouts in Psoriasis, NASH in H2/19
Source: Streetwise Reports  (4/3/19)
Two recently launched clinical trials, and related conference calls, were reviewed in an H.C. Wainwright & Co. report. More >

Best-of-Breed Hemp/CBD Producers
Source: Fincom Investment Partners for Streetwise Reports  (4/2/19)
Fincom Investment Partners surveys the hemp-CBD landscape and discusses two companies it believes are "best of breed." More >

First Cobalt Corp., Oversold, Poised for Rebound This Year?
Source: Peter Epstein for Streetwise Reports  (4/1/19)
Peter Epstein of Epstein Research discusses the market for cobalt and profiles one company whose shares he believes could be at an attractive entry point. More >

Biopharma Hits Milestone in Starting Enrollment for NASH Clinical Trial
Source: Streetwise Reports  (3/30/19)
The company will discuss the trial when it hosts a conference call about this specific disease indication in April. More >

Biopharma's Early Data Show Immunotherapy's Efficacy in Ovarian Cancer
Source: Streetwise Reports  (3/30/19)
The "encouraging" data for this drug candidate as a monotherapy is the focus of an H.C. Wainwright & Co. report. More >

California Gold Entering High-CBD Content Hemp Seed Market in the U.S.
Source: Peter Epstein for Streetwise Reports  (3/28/19)
Peter Epstein of Epstein Research profiles a gold company that plans to grow hemp seed on its land. More >

Premier Health Group Adding Medical Cannabis Support Tool
Source: Streetwise Reports  (3/27/19)
This clinical decision support software integration is the first of its kind, according to the company. More >

San Diego Biopharma Features 'Strong and Balanced Pipeline'
Source: Streetwise Reports  (3/26/19)
An H.C. Wainwright & Co. report discussed what sets this company's asset apart from similar products. More >

Dosing Begins for California Biopharma's Proof-of-Concept Trial in Plaque Psoriasis
Source: Streetwise Reports  (3/25/19)
This U.S. study follows encouraging results from a Phase 1b trial in the same indication in Australia. More >

Biotech Stresses Need to Target Only Toxic Oligomer in Alzheimer's Therapies
Source: Streetwise Reports  (3/25/19)
The company cites the recent discontinuation of other firms' clinical programs as proof. More >

Now Cashed Up, Biopharma to Advance Cholesterol-Lowering Therapy
Source: Streetwise Reports  (3/23/19)
A ROTH Capital Partners report reviewed this New Jersey firm's plans for its lead asset. More >

Several Data Catalysts Expected in 2019 for 'Underappreciated Story'
Source: Streetwise Reports  (3/22/19)
An H.C. Wainwright & Co. report discussed what those are and why they could impact the biotech's valuation. More >

Rare Diseases Biotech Provides Opportunity
Source: Streetwise Reports  (3/21/19)
A ROTH Capital Partners report discussed why the stock price is at its current level and noted upcoming catalysts for the company. More >

Tech Firm to Offer Solution to Inefficient, Expensive Health Clinic Business Model
Source: Streetwise Reports  (3/20/19)
The company will roll out virtual, remote medical services to change how primary care practices are run. More >

Biopharma Expected to Bring 'Two First-in-Class Antibiotics to Market in 2019'
Source: Streetwise Reports  (3/19/19)
The likely timelines for approval and commercialization of each drug are discussed in an H.C. Wainwright report. More >